retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial 3: 28.7% Weight Loss (2026) Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $7.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 19 - Nov 24




























